Emerg Infect Dis. 2024 Nov;30(11):2313-2322. doi: 10.3201/eid3011.240610. Epub 2024 Oct 8.
We conducted a self-controlled case series study to investigate the association between COVID-19 vaccination and facial palsy (FP) in South Korea. We used a large immunization registry linked with the national health information database. We included 44,564,345 patients >18 years of age who received >1 dose of COVID-19 vaccine (BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad.26.COV2.S) and had an FP diagnosis and corticosteroid prescription within 240 days postvaccination. We compared FP incidence in a risk window (days 1-28) with a control window (the remainder of the 240-day observation period, excluding any risk windows). We found 5,211 patients experienced FP within the risk window and 10,531 experienced FP within the control window. FP risk increased within 28 days postvaccination, primarily after first and second doses and was observed for both mRNA and viral vaccines. Clinicians should carefully assess the FP risk-benefit profile associated with the COVID-19 vaccines and monitor neurologic signs after vaccination.
我们进行了一项自身对照病例系列研究，以调查 COVID-19 疫苗接种与韩国面瘫（FP）之间的关联。我们使用了一个与国家健康信息数据库相链接的大型免疫登记处。我们纳入了 44564345 名年龄大于 18 岁的患者，他们接种了 >1 剂 COVID-19 疫苗（BNT162b2、mRNA-1273、ChAdOx1 nCoV-19 或 Ad.26.COV2.S），并在接种后 240 天内出现 FP 诊断和皮质类固醇处方。我们比较了风险窗口（第 1-28 天）和对照窗口（240 天观察期的其余时间，不包括任何风险窗口）内的 FP 发生率。我们发现 5211 名患者在风险窗口内出现 FP，10531 名患者在对照窗口内出现 FP。FP 风险在接种后 28 天内增加，主要发生在第一剂和第二剂之后，并且在 mRNA 和病毒疫苗中均观察到。临床医生应仔细评估与 COVID-19 疫苗相关的 FP 风险效益情况，并在接种后监测神经体征。
